SWOG/ Support |
STUDY | R E G |
O P E N |
ARM | ACCR. GOAL |
TOTAL REGS. |
REGS. LAST 12 Month |
REGS. LAST 6 Month |
REGS. LAST 3 Month |
REGS. LAST 30 DAYS |
REGS. LAST 7 DAYS |
DATE OF FIRST REG. |
# of ACT. INSTs |
# of CURR IRBs |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
SWOG | S1827-SCLC, MRI Surveillance +/- PCI | 1 | Y | 1 PCI + MRI brain surveillance | 668 | 136 | 31 | 17 | 10 | 4 | 1 | 05/04/2020 | 335 | 128 |
2 MRI brain surveillance | 133 | 29 | 16 | 8 | 2 | 0 | ||||||||
269 | 60 | 33 | 18 | 6 | 1 | |||||||||
S1933-NSCLC, Stg II-III, RT + Atezo | 1 | Y | 1 Hypofractionated Radiotherapy | 47 | 43 | 8 | 4 | 3 | 0 | 0 | 01/13/2021 | 105 | 40 | |
43 | 8 | 4 | 3 | 0 | 0 | |||||||||
2 | Y | 2 Atezolizumab | 33 | 6 | 2 | 2 | 2 | 0 | 01/13/2021 | |||||
33 | 6 | 2 | 2 | 2 | 0 | |||||||||
Yes | A081801-ALCHEMIST4, ALK and EGFR negative, Chemo-IO | 1 | E | Total Registrations | 88 | 15 | 4 | 1 | 1 | 1 | 10/20/2020 | 413 | 173 | |
88 | 15 | 4 | 1 | 1 | 1 | |||||||||
EA5162-NSCLC,StgIV/IIB,EGFR exon20 insertion,AZD9291 | 1 | E | Total Registrations | 3 | 2 | 2 | 2 | 0 | 0 | 08/23/2023 | 67 | 32 | ||
3 | 2 | 2 | 2 | 0 | 0 | |||||||||
EA5182-NSCLC, Met EGFR mut, AZD9291+Beva vs AZD9291 | 1 | E | Total Registrations | 22 | 8 | 2 | 1 | 1 | 1 | 04/28/2021 | 180 | 82 | ||
22 | 8 | 2 | 1 | 1 | 1 | |||||||||
EA5221-Lung, Advanced NSCLC, ChemoImmuno/Immuno | 1 | E | Total Registrations | 2 | 2 | 1 | 1 | 0 | 0 | 08/07/2024 | 174 | 71 | ||
2 | 2 | 1 | 1 | 0 | 0 | |||||||||
2 | E | Total Registrations | 2 | 2 | 1 | 1 | 0 | 0 | 08/07/2024 | |||||
2 | 2 | 1 | 1 | 0 | 0 | |||||||||
NRGLU008-Lung NSCL, StgII-III, StereoBodyRad/MedChemo | 1 | E | Total Registrations | 2 | 1 | 0 | 0 | 0 | 0 | 01/26/2024 | 281 | 111 | ||
2 | 1 | 0 | 0 | 0 | 0 | |||||||||
No | A082002-Lung, Adv, Systemic Tx +/- SBRT | 1 | E | Total Registrations | 4 | 0 | 0 | 0 | 0 | 0 | 10/12/2022 | 218 | 67 | |
4 | 0 | 0 | 0 | 0 | 0 | |||||||||
Study | Registration/Phase | Open Date | # of ACT. INSTs |
# of CURR IRBs |
---|---|---|---|---|
S2414 NSCLC, Stg II-IIIB, Durva vs Surveillance | 1 Randomization | 14-Mar-25 | 6 | 1 |